1. Scrip

Video: Chris Viehbacher Interviewed At BioPharm America

 
• By Joseph Haas

Since his departure from Sanofi, Christopher Viehbacher has taken on a significant role in venture capital. At the BioPharm America 2015 conference in Boston, Massachusetts, he spoke about his company's business model and goals, as well as the trend of pharma execs moving into smaller companies.

Since his departure from Sanofi, Christopher Viehbacher has taken on a significant role in venture capital. At the BioPharm America 2015 conference in Boston, Massachusetts, he spoke about his company's business model and goals, as well as the trend of pharma execs moving into smaller companies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.